Biopharmaceutical Contract Development and Manufacturing Organization Market
Dublin, Aug. 13, 2026 (GLOBE NEWSWIRE) — The “Biopharmaceutical Contract Development and Manufacturing Organization Market 2026-2033” has been added to ResearchAndMarkets.com’s offering.
The global biopharmaceutical contract development and manufacturing organization market was valued at USD 27.3 billion in 2025 and is projected to increase from USD 29.8 billion in 2026 to USD 56.6 billion by 2033. The market is expected to record a compound annual growth rate (CAGR) of 9.6% from 2026 to 2033. North America led the global biopharmaceutical CDMO market in 2025, accounting for a 43.8% revenue share.
Rising demand for biologics, biosimilars, and advanced therapies is accelerating market expansion. Biopharmaceutical manufacturers are increasingly outsourcing development and production activities to specialized CDMOs to improve cost efficiency, access advanced technical capabilities, expand manufacturing capacity, and reduce time to market. The continued growth of global drug pipelines is also creating sustained demand for contract development, manufacturing, packaging, regulatory, storage, and logistics services.
Biologics and biosimilars remain central to the industry’s growth outlook as pharmaceutical and biotechnology companies prioritize targeted and personalized treatments for cancer, autoimmune diseases, rare genetic conditions, and other complex or chronic disorders. Patent expirations, increasing demand for high-value therapies, and the commercial potential of blockbuster biologic products are strengthening development pipelines. Specialized biopharmaceutical CDMOs are benefiting from this trend by providing scalable infrastructure, technical expertise, and integrated services across clinical and commercial workflows.
The pharmaceutical industry continues to shift investment toward complex large-molecule products, even as small molecules retain a substantial share of marketed drugs. Developing and manufacturing biologics requires sophisticated production processes, rigorous quality controls, and specialized facilities. These requirements are encouraging biopharmaceutical companies to establish long-term partnerships with external development and manufacturing providers capable of supporting products from early-stage development through commercial production.
Technological innovation is further improving the capabilities and competitiveness of biopharmaceutical contract development and manufacturing organizations. Single-use bioprocessing systems, continuous manufacturing, advanced cell-line development platforms, process intensification, and enhanced analytical testing are supporting higher productivity and more reliable production. CDMOs are also adopting artificial intelligence, machine learning, and digital process automation to optimize operations, strengthen quality assurance, improve process consistency, and support data-driven decision-making.
Investments in global manufacturing networks are expected to remain a major biopharmaceutical CDMO market trend through 2033. Companies are expanding bioreactor capacity, upgrading specialized production facilities, and strengthening cold-chain logistics to support complex biologics. Strategic agreements between CDMOs and pharmaceutical or biotechnology companies are also creating long-term supply relationships, increasing market resilience, and supporting the commercialization of next-generation therapies.
Biopharmaceutical CDMO Market Report Segmentation
The report evaluates revenue growth at global, regional, and country levels and analyzes industry trends across market segments from 2021 to 2033. The study segments the global biopharmaceutical contract development and manufacturing organization market by type, product, service, source, workflow, therapeutic area, end use, and region.
Type Outlook (Revenue, USD Million, 2021-2033)
- Active Pharmaceutical Ingredient (API)
- Finished Drug Product
- Others
Product Outlook (Revenue, USD Million, 2021-2033)
- Biologics
- Biosimilars
Service Outlook (Revenue, USD Million, 2021-2033)
- Contract Development
- Contract Manufacturing
- Packaging and Labeling
- Regulatory Affairs
- Logistics and Storage
- Others
Source Outlook (Revenue, USD Million, 2021-2033)
- Mammalian
- Microbial
Workflow Outlook (Revenue, USD Million, 2021-2033)
- Clinical
- Commercial
Therapeutic Area Outlook (Revenue, USD Million, 2021-2033)
- Oncology
- Infectious Diseases
- Neurological Disorders
- Cardiovascular Disease
- Metabolic Disorders
- Autoimmune Diseases
- Respiratory Diseases
- Ophthalmology
- Gastrointestinal Disorders
- Others
End-Use Outlook (Revenue, USD Million, 2021-2033)
- Large Pharmaceutical and Biotechnology Companies
- Small and Mid-Sized Pharmaceutical and Biotechnology Companies
- Academic Research and Government Institutes
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Key Attributes
| Report Attribute | Details |
| No. of Pages | 150 |
| Forecast Period | 2025-2033 |
| Estimated Market Value (USD) in 2025 | $27.3 Billion |
| Forecasted Market Value (USD) by 2033 | $56.6 Billion |
| Compound Annual Growth Rate | 9.6% |
| Regions Covered | Global |
Companies Featured
- Lonza Group
- Thermo Fisher Scientific
- Catalent Pharma Solutions
- Samsung Biologics
- WuXi Biologics / WuXi AppTec
- Boehringer Ingelheim (Biopharma CDMO)
- Fujifilm Diosynth Biotechnologies
- Charles River Laboratories
- AGC Biologics
- Siegfried Holding
- Recipharm
- MilliporeSigma (Merck KGaA)
- Biocon Biologics
- Sandoz
- Rentschler Biopharma SE
For more information about this report visit https://www.researchandmarkets.com/r/k071u2
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
- Biopharmaceutical Contract Development and Manufacturing Organization Market
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
